This year's agenda will have a strong focus on the future of pricing and reimbursement. Other key topics include:
- Updates on AMNOG and its implication on pricing and reimbursement
- How biosimilars are affecting your pricing strategy
- Capture on emerging markets’ regulatory framework to adapt your market access and P&R models
- Orphan drugs using recent examples to highlight the impact on pricing
- Cancer drug funding and budget cuts in the UK
- Innovative solutions beyond the pill
- Japanese and Turkish regional updates
- Updates on AMNOG and its implication on pricing and reimbursement
- How biosimilars are affecting your pricing strategy
- Capture on emerging markets’ regulatory framework to adapt your market access and P&R models
- Orphan drugs using recent examples to highlight the impact on pricing
- Cancer drug funding and budget cuts in the UK
- Innovative solutions beyond the pill
- Japanese and Turkish regional updates
